11.06.13
It's been quite a busy fall for Biotronik SE & Co. KG.
The German cardiovascular device developer has launched roughly a half-dozen products since the end of September, including a gold-tipped catheter (AlCath Flutter Gold), percutaneous transluminal angioplasty balloon (Passeo-35), drug-eluting stents (new 35 mm and 40 mm versions of Orsiro) and implantable cardioverter/cardiac resynchronization therapy defibrillators (Ilesto).
The company's latest product debut is the Idova 7 implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D). The devices offer ultrahigh-energy therapy without compromising on short charge times (10 sec), smaller size (34 cc), and outstanding longevity of more than 11 years. The Idova products are designed to stop life-threatening arrhythmias with the very first shock, Biotronik claims.
As the only device on the market approved for magnetic resonance imaging that also offers 45 joule, Idova 7 is engineered to increase the success rate of the first shock and reduce the need for subsequent shocks. "Ideally, a patient's heart would react the same way to ICD therapy in real life as it would when tested after implantation. But that is not so often the case," commented Clemens Steinwender, M.D., of General Hospital Linz in Austria. "If I can give my patients that extra energy at the first shock, then I can assure them they are on the safe side."
For ICD therapy to be successful, it is crucial to be aware of a patient's defibrillation threshold (DFT), defined as the amount of energy required to shock the heart back to a normal rhythm. But DFT has a tendency to rise over time, and require higher amounts of energy. Higher DFTs can be caused by factors as widespread as prescribed medication, severely dilated hearts, or young age and high activity levels.
"There are many variables that are related to the patient's health and lifestyle, and not under my direct control. These can unfortunately affect defibrillation thresholds without our advanced knowledge," explained Fabrizio Caravati, M.D., of Hospital Fondazione Macchi in Varese, Italy. "It is important to be able to reassure patients that they have the maximum amount of energy at their disposal, in the event they should need it," agreed Caravati's colleague, Paolo Bonfanti, M.D.
"After launching Ilesto and Iforia, we can now broaden our second generation of ProMRI devices with the ultrahigh-energy Idova 7 series," Christoph Böhmer, president international at Biotronik, said. "Like all Biotronik implants, Idova 7 will also be available with Biotronik Home Monitoring, which rapidly detects clinically relevant events like arrhythmias and can thereby prevent stroke and reduce hospitalization. In fact, the results of the recent In-Time study demonstrated a significant reduction in all-cause mortality in heart failure patients with implant-based remote monitoring."
Biotronik is headquartered in Berlin, Germany, and has a global workforce of more than 5,600 employees. U.S. headquarters are in Lake Oswego, Ore.
The German cardiovascular device developer has launched roughly a half-dozen products since the end of September, including a gold-tipped catheter (AlCath Flutter Gold), percutaneous transluminal angioplasty balloon (Passeo-35), drug-eluting stents (new 35 mm and 40 mm versions of Orsiro) and implantable cardioverter/cardiac resynchronization therapy defibrillators (Ilesto).
The company's latest product debut is the Idova 7 implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D). The devices offer ultrahigh-energy therapy without compromising on short charge times (10 sec), smaller size (34 cc), and outstanding longevity of more than 11 years. The Idova products are designed to stop life-threatening arrhythmias with the very first shock, Biotronik claims.
As the only device on the market approved for magnetic resonance imaging that also offers 45 joule, Idova 7 is engineered to increase the success rate of the first shock and reduce the need for subsequent shocks. "Ideally, a patient's heart would react the same way to ICD therapy in real life as it would when tested after implantation. But that is not so often the case," commented Clemens Steinwender, M.D., of General Hospital Linz in Austria. "If I can give my patients that extra energy at the first shock, then I can assure them they are on the safe side."
For ICD therapy to be successful, it is crucial to be aware of a patient's defibrillation threshold (DFT), defined as the amount of energy required to shock the heart back to a normal rhythm. But DFT has a tendency to rise over time, and require higher amounts of energy. Higher DFTs can be caused by factors as widespread as prescribed medication, severely dilated hearts, or young age and high activity levels.
"There are many variables that are related to the patient's health and lifestyle, and not under my direct control. These can unfortunately affect defibrillation thresholds without our advanced knowledge," explained Fabrizio Caravati, M.D., of Hospital Fondazione Macchi in Varese, Italy. "It is important to be able to reassure patients that they have the maximum amount of energy at their disposal, in the event they should need it," agreed Caravati's colleague, Paolo Bonfanti, M.D.
"After launching Ilesto and Iforia, we can now broaden our second generation of ProMRI devices with the ultrahigh-energy Idova 7 series," Christoph Böhmer, president international at Biotronik, said. "Like all Biotronik implants, Idova 7 will also be available with Biotronik Home Monitoring, which rapidly detects clinically relevant events like arrhythmias and can thereby prevent stroke and reduce hospitalization. In fact, the results of the recent In-Time study demonstrated a significant reduction in all-cause mortality in heart failure patients with implant-based remote monitoring."
Biotronik is headquartered in Berlin, Germany, and has a global workforce of more than 5,600 employees. U.S. headquarters are in Lake Oswego, Ore. - See more at: http://www.mpo-mag.com/contents/view_breaking-news/2013-10-02/biotronik-rolls-out-new-line-of-defibrillators/#sthash.jpWvjY3M.dpuf
Biotronik is headquartered in Berlin, Germany, and has a global workforce of more than 5,600 employees. U.S. headquarters are in Lake Oswego, Ore.
Biotronik is headquartered in Berlin, Germany, and has a global workforce of more than 5,600 employees. U.S. headquarters are in Lake Oswego, Ore. - See more at: http://www.mpo-mag.com/contents/view_breaking-news/2013-10-02/biotronik-rolls-out-new-line-of-defibrillators/#sthash.jpWvjY3M.dpuf